Table 2. Predictors of rapid virological response among treated HCV and HCV/HIV infected participants with recently acquired HCV infection adherent to therapy (n = 85*).
| RVR(n = 43)n, (%)£ | Unadjustedodds ratio(95% CI) | P | Poverall | Adjustedodds ratio(95% CI) | P | |
| Male Sex (vs. female sex) | 31 (49) | 1.24 (0.47, 3.28) | 0.667 | – | – | – |
| Injection drug use in previous 30 days (vs. none) | 13 (50) | 1.00 (0.40, 2.52) | 1.000 | – | – | – |
| Social support | ||||||
| ≤14 | 23 (46) | 1.00 | – | – | – | – |
| >14 | 17 (65) | 2.22 (0.83, 5.91) | 0.112 | 0.161 | – | – |
| Missing | 3 (33) | 0.59 (0.13, 2.61) | 0.484 | – | – | – |
| IL28B genotype | ||||||
| rs8099917 favorable TT (vs. GT/GG) | 27 (55) | 1.67 (0.68, 4.06) | 0.262 | – | – | – |
| rs12979860 favorable CC (vs. CT/TT) | 22 (55) | 1.54 (0.65, 3.67) | 0.326 | – | – | – |
| Estimated duration of HCV infection of ≥26 wks atbaseline (vs. <26 weeks) | 30 (46) | 0.46 (0.16, 1.31) | 0.145 | – | 0.23 (0.06, 0.87) | 0.031 |
| Presentation of recent HCV | ||||||
| Acute clinical (symptomatic) | 18 (56) | 1.00 | – | – | – | – |
| Acute clinical (ALT >400 IU/mL) | 7 (35) | 0.42 (0.13, 1.33) | 0.139 | 0.288 | – | – |
| Asymptomatic seroconversion | 18 (55) | 0.93 (0.35, 2.48) | 0.890 | – | – | – |
| HCV RNA ≥5.6 log10 (IU/mL) at baseline(vs. <5.6 log10) | 7 (21) | 0.11 (0.04, 0.30) | <0.001 | – | 0.09 (0.03, 0.30) | <0.001 |
| HCV genotype | ||||||
| Genotype 1¥ | 18 (39) | 1.00 | – | – | – | – |
| Genotype 2/3 | 22 (61) | 2.44 (1.00, 5.98) | 0.050 | – | 3.31 (1.11, 9.90) | 0.032 |
| Received ribavirin/HIV infection | 13 (43) | 0.64 (0.26, 1.56) | 0.324 | – | 0.71 (0.23, 2.25) | 0.563 |
| IP-10 at enrolment | Adjusted | |||||
| Log IP-10/per unit increase | – | 0.17 (0.03, 0.84) | 0.030 | – | 0.30 (0.04, 2.19) | 0.235 |
| ≥150 pg/mL | 20 (40) | 0.33 (0.11, 1.03) | 0.057 | – | 0.44 (0.11, 1.80) | 0.252 |
| ≥380 pg/mL | 5 (29) | 0.37 (0.11, 1.20) | 0.100 | – | 0.44 (0.11, 1.80) | 0.251 |
| ≥600 pg/mL | 1 (11) | 0.11 (0.01, 0.96) | 0.046 | – | 0.19 (0.02, 2.25) | 0.189 |
*
four of the 89 adherent participants did not have evaluable HCV RNA at week 4 and were excluded from this analysis,
¥
includes one participant with mixed genotype 1/3 infection,
£
row percentage (e.g. proportion with cRVR). RVR, rapid virological response; CI, confidence interval.